Table 1

Population characteristics at time of TNFi discontinuation (N=325)

Age (years)52.6±13.1
Female168 (51.9%)
BMI (kg/m2)
 Normal61 (19.1%)
 Overweight113 (34.8%)
 Obese150 (46.1%)
Duration of PsA (years)9.8±8.1
Duration of TNFi (years)1.5±1.6
Tender joint count (mean±SD)0.66±1.13
Swollen joint count (mean±SD)0.38±0.83
Patient global assessment (mean±SD)20.2±19.0
Physician global assessment (mean±SD)8.6±8.6
CDAI (mean±SD)3.9±2.8
mHAQ (mean±SD)0.20±0.32
mDAS (mean±SD)2.4±0.6
TNFi use
 1st TNFi171 (52.6%)
 2nd TNFi101 (31.3%)
 3rd TNFi46 (14.2%)
 4th TNFi7 (2.1%)
TNFi monotherapy174 (53.5%)
TNFi+MTX137 (42.4%)
TNFi+prednisone24 (7.4%)
  • BMI, body mass index; CDAI, clinical disease activity index; mDAS, modified disease activity score; mHAQ, modified health assessment questionnaire; PsA, psoriatic arthritis; TNFi, tumour necrosis factor inhibitor.